Kazano is owned by Takeda Pharms Usa.
Kazano contains Alogliptin Benzoate; Metformin Hydrochloride.
Kazano has a total of 4 drug patents out of which 0 drug patents have expired.
Kazano was authorised for market use on 25 January, 2013.
Kazano is available in tablet;oral dosage forms.
Kazano can be used as method of treating diabetes comprising administering alogliptin, method of treating diabetes comprising administering a compound such as alogliptin.
The generics of Kazano are possible to be released after 24 May, 2029.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8288539 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2025
(2 years from now) | |
US7807689 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2028
(5 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8173663 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(1 year, 11 months from now) | |
US8900638 | TAKEDA PHARMS USA | Solid preparation comprising alogliptin and metformin hydrochloride |
May, 2029
(6 years from now) |
Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 25 January, 2013
Treatment: Method of treating diabetes comprising administering a compound such as alogliptin; Method of treating diabetes comprising administering alogliptin
Dosage: TABLET;ORAL
12
United States
9
China
7
Japan
3
Israel
3
Argentina
3
Korea, Republic of
3
Taiwan, Province of China
2
South Africa
2
Australia
2
Morocco
2
Norway
2
Costa Rica
2
Brazil
2
Malaysia
2
Spain
2
Peru
2
Georgia
2
Ukraine
2
EA
2
Canada
2
New Zealand
2
European Union
1
Denmark
1
Austria
1
Mexico
1
Jordan
1
Hong Kong
1
Slovenia
1
Hungary
1
Germany
1
Colombia
1
Croatia
1
Portugal
1
Cyprus
1
Netherlands
1
Dominican Republic
1
Poland
1
RS
1
Luxembourg
1
Ecuador
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic